CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Acura Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Acura Pharmaceuticals Inc
616 N. North Court
Suite 120
Phone: (847) 705-7709p:847 705-7709 Palatine, IL  60067-8121  United States Ticker: ACURACUR

Business Summary
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202112/31/2021YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer, Director Robert B.Jones 62 7/7/2011 4/7/2008
Chief Financial Officer, Senior Vice President, Secretary Peter A.Clemens 68 8/1/2004 2/19/1998
Vice President, Corporate Controller, Treasurer Robert A.Seiser 57 4/1/2004 3/1/1998
5 additional Officers and Directors records available in full report.

Business Names
Business Name
`Acura Pharmaceuticals, Inc.
ACUR
Acura Pharmaceutical Technologies, Inc.
Acura Pharmaceuticals, Inc.

General Information
Number of Employees: 14 (As of 12/31/2017)
Outstanding Shares: 66,001,783 (As of 4/30/2023)
Shareholders: 301
Stock Exchange: OTC
Federal Tax Id: 110853640
Fax Number: (847) 705-5399
Email Address: investor@halseydrug.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024